17 research outputs found
An Extended TopoART Network for the Stable On-Line Learning of Regression Functions
Tscherepanow M. An Extended TopoART Network for the Stable On-Line Learning of Regression Functions. In: Lu B-L, Zhang L, Kwok J, eds. Neural Information Processing : 18th International Conference, ICONIP 2011, November 13-17, 2011, Proceedings, Part II. Lecture notes in computer science, 7063. Berlin: Springer; 2011: 562-571.In this paper, a novel on-line regression method is presented. Due to its origins in Adaptive Resonance Theory neural networks, this method is particularly well-suited to problems requiring stable incremental learning. Its performance on five publicly available datasets is shown to be at least comparable to two established off-line methods. Furthermore, it exhibits considerable improvements in comparison to its closest supervised relative Fuzzy ARTMAP
The Neutralization of Interferons by Antibody. I. Quantitative and Theoretical Analyses of the Neutralization Reaction in Different Bioassay Systems
Kidnapping Public Schooling: Perversion and Normalization of the Discursive Bases within the Epicenter of New Right Educational Policies
Cholinesterase Inhibitors for Alzheimer Disease: Multitargeting Strategy based on Anti-Alzheimer's Drugs Repositioning
International audienceIn the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters. During the advancement of Alzheimer's disease (AD) cholinergic deficits occur and this can lead to extensive cognitive dysfunction and decline. Acetylcholinesterase (AChE) remains a highly feasible target for the symptomatic improvement of AD. Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvementin AD because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibitingperipheral AChE for myasthenia gravis had effectively proven that AChE inhibition was a reachable therapeutictarget. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for thesymptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEIs) have been continued to bedeveloped. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper,we summarize the different types of ChEIs which are under development and their respective mechanisms ofactions